Kepos Capital LP Regeneron Pharmaceuticals, Inc. Transaction History

Kepos Capital LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$336.18 - $494.43 $665,300 - $978,476	-1,979 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$274.13 - $376.51 $542,503 - $745,113	1,979 New	1,979 $743,000
Q3 2019 Nov 13, 2019	SELL	$273.46 - $318.39 $2.34 Million - $2.73 Million	-8,572 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$299.6 - $414.82 $1.86 Million - $2.58 Million	-6,224 Reduced 42.07%	8,572 $2.68 Million
Q1 2019 May 13, 2019	SELL	$372.08 - $439.57 $815,971 - $963,977	-2,193 Reduced 12.91%	14,796 $6.08 Million
Q4 2018 Feb 13, 2019	BUY	$335.82 - $403.04 $4.1 Million - $4.92 Million	12,216 Added 255.94%	16,989 $6.35 Million
Q3 2018 Nov 13, 2018	BUY	$351.14 - $408.51 $1.68 Million - $1.95 Million	4,773 New	4,773 $1.93 Million
Q2 2018 Aug 13, 2018	SELL	$284.6 - $344.99 $2.59 Million - $3.14 Million	-9,098 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$315.82 - $393.78 $1.06 Million - $1.33 Million	-3,369 Reduced 27.02%	9,098 $3.13 Million
Q4 2017 Feb 12, 2018	BUY	$358.63 - $469.95 $1.9 Million - $2.49 Million	5,291 Added 73.73%	12,467 $4.69 Million
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $3.1 Million - $3.62 Million	7,176	7,176 $3.21 Million

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.8B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Kepos Capital LP, based on Form 13F filings with the SEC.

Stay updated on Kepos Capital LP with notifications on news.